JP2017507900A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017507900A5 JP2017507900A5 JP2016539949A JP2016539949A JP2017507900A5 JP 2017507900 A5 JP2017507900 A5 JP 2017507900A5 JP 2016539949 A JP2016539949 A JP 2016539949A JP 2016539949 A JP2016539949 A JP 2016539949A JP 2017507900 A5 JP2017507900 A5 JP 2017507900A5
- Authority
- JP
- Japan
- Prior art keywords
- her2
- optionally
- seq
- antibody
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 claims 25
- 239000005557 antagonist Substances 0.000 claims 23
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 201000011510 cancer Diseases 0.000 claims 14
- 239000000427 antigen Substances 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- 239000003937 drug carrier Substances 0.000 claims 11
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 10
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 10
- 230000035772 mutation Effects 0.000 claims 9
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 7
- 102000048776 human CD274 Human genes 0.000 claims 7
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 6
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 6
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 6
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 238000006467 substitution reaction Methods 0.000 claims 4
- 238000011460 HER2-targeted therapy Methods 0.000 claims 3
- 108091008874 T cell receptors Proteins 0.000 claims 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 3
- 229960000575 trastuzumab Drugs 0.000 claims 3
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims 2
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229960002087 pertuzumab Drugs 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 230000036737 immune function Effects 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007914 intraventricular administration Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 230000003389 potentiating effect Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361917264P | 2013-12-17 | 2013-12-17 | |
| US61/917,264 | 2013-12-17 | ||
| PCT/US2014/070992 WO2015095418A1 (en) | 2013-12-17 | 2014-12-17 | Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019074325A Division JP2019142900A (ja) | 2013-12-17 | 2019-04-09 | Ｐｄ−１軸結合アンタゴニスト及び抗ｈｅｒ２抗体を使用してｈｅｒ２陽性がんを治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017507900A JP2017507900A (ja) | 2017-03-23 |
| JP2017507900A5 true JP2017507900A5 (enExample) | 2018-02-08 |
Family
ID=52293262
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016539949A Withdrawn JP2017507900A (ja) | 2013-12-17 | 2014-12-17 | Ｐｄ−１軸結合アンタゴニスト及び抗ｈｅｒ２抗体を使用してｈｅｒ２陽性がんを治療する方法 |
| JP2016539319A Active JP6841656B2 (ja) | 2013-12-17 | 2014-12-17 | Ｐｄ−１軸結合アンタゴニスト及びタキサンを使用する癌の治療方法 |
| JP2019074325A Pending JP2019142900A (ja) | 2013-12-17 | 2019-04-09 | Ｐｄ−１軸結合アンタゴニスト及び抗ｈｅｒ２抗体を使用してｈｅｒ２陽性がんを治療する方法 |
| JP2020034955A Withdrawn JP2020111580A (ja) | 2013-12-17 | 2020-03-02 | Ｐｄ−１軸結合アンタゴニスト及びタキサンを使用する癌の治療方法 |
| JP2022000201A Active JP7645204B2 (ja) | 2013-12-17 | 2022-01-04 | Ｐｄ－１軸結合アンタゴニスト及びタキサンを使用する癌の治療方法 |
| JP2024179266A Pending JP2025020147A (ja) | 2013-12-17 | 2024-10-11 | Ｐｄ－１軸結合アンタゴニスト及びタキサンを使用する癌の治療方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016539319A Active JP6841656B2 (ja) | 2013-12-17 | 2014-12-17 | Ｐｄ−１軸結合アンタゴニスト及びタキサンを使用する癌の治療方法 |
| JP2019074325A Pending JP2019142900A (ja) | 2013-12-17 | 2019-04-09 | Ｐｄ−１軸結合アンタゴニスト及び抗ｈｅｒ２抗体を使用してｈｅｒ２陽性がんを治療する方法 |
| JP2020034955A Withdrawn JP2020111580A (ja) | 2013-12-17 | 2020-03-02 | Ｐｄ−１軸結合アンタゴニスト及びタキサンを使用する癌の治療方法 |
| JP2022000201A Active JP7645204B2 (ja) | 2013-12-17 | 2022-01-04 | Ｐｄ－１軸結合アンタゴニスト及びタキサンを使用する癌の治療方法 |
| JP2024179266A Pending JP2025020147A (ja) | 2013-12-17 | 2024-10-11 | Ｐｄ－１軸結合アンタゴニスト及びタキサンを使用する癌の治療方法 |
Country Status (27)
| Country | Link |
|---|---|
| US (13) | US10570213B2 (enExample) |
| EP (4) | EP3083686B2 (enExample) |
| JP (6) | JP2017507900A (enExample) |
| KR (5) | KR20240017102A (enExample) |
| CN (3) | CN105828837B (enExample) |
| AU (3) | AU2014364587C1 (enExample) |
| BR (1) | BR112016013896A2 (enExample) |
| CA (2) | CA2931812A1 (enExample) |
| DK (1) | DK3083686T4 (enExample) |
| ES (1) | ES2763429T5 (enExample) |
| FI (1) | FI3083686T4 (enExample) |
| HK (1) | HK1225634A1 (enExample) |
| HR (1) | HRP20192288T4 (enExample) |
| HU (1) | HUE047699T2 (enExample) |
| IL (3) | IL296657A (enExample) |
| LT (1) | LT3083686T (enExample) |
| MX (3) | MX2016007887A (enExample) |
| MY (1) | MY189089A (enExample) |
| NZ (2) | NZ760065A (enExample) |
| PL (1) | PL3083686T5 (enExample) |
| PT (1) | PT3083686T (enExample) |
| RS (1) | RS59659B2 (enExample) |
| RU (1) | RU2719487C2 (enExample) |
| SG (4) | SG10201808519VA (enExample) |
| SI (1) | SI3083686T2 (enExample) |
| WO (2) | WO2015095404A2 (enExample) |
| ZA (1) | ZA201603753B (enExample) |
Families Citing this family (149)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| PT2376535T (pt) | 2008-12-09 | 2017-06-23 | Hoffmann La Roche | Anticorpos anti-pd-l1 e a sua utilização para a melhoria do funcionamento das células t |
| WO2013026839A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
| PL4234033T3 (pl) | 2011-10-14 | 2025-04-28 | F. Hoffmann-La Roche Ag | Zastosowania i wyrób przemysłowy zawierający pertuzumab, inhibitor dimeryzacji HER2 |
| BR112015007120A2 (pt) | 2012-10-08 | 2017-12-12 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo |
| PT2961771T (pt) | 2013-02-26 | 2020-02-28 | Roche Glycart Ag | Moléculas de ligação ao antigénio biespecíficas para ativação das células t, específicas para cd3 e cea |
| CN105143270B (zh) | 2013-02-26 | 2019-11-12 | 罗切格利卡特公司 | 双特异性t细胞活化抗原结合分子 |
| EP3800204A1 (en) | 2013-04-16 | 2021-04-07 | F. Hoffmann-La Roche AG | Pertuzumab variants and evaluation thereof |
| EP3003316B1 (en) * | 2013-05-31 | 2020-07-22 | Merck Sharp & Dohme Corp. | Combination therapies for cancer |
| BR112016000853A2 (pt) | 2013-07-16 | 2017-12-12 | Genentech Inc | métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit |
| SG11201600853UA (en) | 2013-08-05 | 2016-03-30 | Twist Bioscience Corp | De novo synthesized gene libraries |
| AU2014361473B2 (en) | 2013-12-12 | 2019-09-26 | Jiangsu Hengrui Medicine Co., Ltd. | PD-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| EP3736292B1 (en) | 2013-12-17 | 2024-05-08 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| LT3083686T (lt) * | 2013-12-17 | 2020-01-10 | F. Hoffmann-La Roche Ag | Vėžinių ligų gydymo būdai naudojant pd-1 ašies rišimosi antagonistus ir taksanus |
| SG11201605824XA (en) | 2014-02-04 | 2016-08-30 | Pfizer | Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer |
| MX2016012779A (es) | 2014-03-31 | 2017-04-27 | Genentech Inc | Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40. |
| US11820832B2 (en) | 2014-07-25 | 2023-11-21 | Memorial Sloan Kettering Cancer Center | Bispecific HER2 and CD3 binding molecules |
| MX386342B (es) | 2014-07-25 | 2025-03-18 | Memorial Sloan Kettering Cancer Center | Móleculas de unión a her2 y cd3 biespecíficas. |
| FI3608337T3 (fi) | 2014-08-04 | 2024-06-13 | Hoffmann La Roche | Bispesifisiä t-solua aktivoivia antigeenia sitovia molekyylejä |
| WO2016033555A1 (en) * | 2014-08-28 | 2016-03-03 | Halozyme, Inc. | Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor |
| KR20170066421A (ko) | 2014-09-12 | 2017-06-14 | 제넨테크, 인크. | 항-cll-1 항체 및 면역접합체 |
| MX387463B (es) | 2014-11-20 | 2025-03-18 | Hoffmann La Roche | Moléculas de unión a antígeno biespecíficas activadoras de células t y antagonistas de unión al eje de pd-1 y usos de los mismos para el tratamiento de cáncer. |
| CN107074955B (zh) | 2014-11-20 | 2021-06-22 | 豪夫迈·罗氏有限公司 | 针对FolR1和CD3的T细胞活化性双特异性抗原结合分子 |
| RS60615B1 (sr) | 2014-11-20 | 2020-08-31 | Hoffmann La Roche | Zajednički laki lanci i postupci upotrebe |
| BR112017011536A2 (pt) * | 2014-12-02 | 2018-02-27 | Celgene Corp | terapias de combinação |
| AR102918A1 (es) | 2014-12-05 | 2017-04-05 | Genentech Inc | Anticuerpos anti-cd79b y métodos de uso |
| EP4279087A3 (en) | 2015-02-26 | 2024-01-31 | Merck Patent GmbH | Pd-1 / pd-l1 inhibitors for the treatment of cancer |
| EP3268392A2 (en) | 2015-03-13 | 2018-01-17 | CytomX Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| CN114380909A (zh) | 2015-03-30 | 2022-04-22 | 斯特库比股份有限公司 | 特异性针对糖基化的pd-l1的抗体及其使用方法 |
| US11933786B2 (en) | 2015-03-30 | 2024-03-19 | Stcube, Inc. | Antibodies specific to glycosylated PD-L1 and methods of use thereof |
| US9981239B2 (en) | 2015-04-21 | 2018-05-29 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
| CA3026452C (en) | 2015-06-04 | 2023-03-21 | Crititech, Inc. | Nozzle assembly and methods for use |
| TWI870335B (zh) | 2015-06-12 | 2025-01-21 | 美商宏觀基因股份有限公司 | 變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用 |
| PL3310814T3 (pl) | 2015-06-16 | 2023-12-11 | F. Hoffmann-La Roche Ag | Humanizowane i wykazujące dojrzałe powinowactwo przeciwciała przeciwko FcRH5 i sposoby stosowania |
| WO2016205200A1 (en) | 2015-06-16 | 2016-12-22 | Genentech, Inc. | Anti-cll-1 antibodies and methods of use |
| PH12017501857B1 (en) | 2015-06-16 | 2024-01-17 | Merck Patent Gmbh | Pd-l1 antagonist combination treatments |
| WO2016204966A1 (en) | 2015-06-16 | 2016-12-22 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| KR102689256B1 (ko) | 2015-06-17 | 2024-07-30 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법 |
| JP7014706B2 (ja) | 2015-07-13 | 2022-02-01 | サイトメックス セラピューティクス インコーポレイテッド | 抗ｐｄ－１抗体、活性化可能抗ｐｄ－１抗体、およびその使用方法 |
| EP3331542A4 (en) | 2015-08-03 | 2019-04-03 | ENB Therapeutics, LLC | COMPOSITIONS AND METHODS OF TREATING CANCER ASSOCIATED WITH ETBR ACTIVATION |
| EP3337826A1 (en) | 2015-08-20 | 2018-06-27 | Sutro Biopharma, Inc. | Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies |
| AU2016324296A1 (en) | 2015-09-18 | 2018-04-12 | Twist Bioscience Corporation | Oligonucleic acid variant libraries and synthesis thereof |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| MA43025A (fr) | 2015-10-02 | 2021-05-26 | Hoffmann La Roche | Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t anti-ceaxcd3 |
| PE20240096A1 (es) | 2015-10-02 | 2024-01-18 | Hoffmann La Roche | Anticuerpos biespecificos especificos para un receptor de tnf coestimulador |
| HK1251475A1 (zh) | 2015-10-08 | 2019-02-01 | Macrogenics, Inc. | 用於癌症治疗的联合疗法 |
| CA3001264A1 (en) * | 2015-10-30 | 2017-05-04 | Affibody Ab | Pd-l1 binding polypeptide |
| EP3368557A1 (en) | 2015-10-30 | 2018-09-05 | Affibody AB | New polypeptide |
| CN115920796A (zh) | 2015-12-01 | 2023-04-07 | 特韦斯特生物科学公司 | 功能化表面及其制备 |
| WO2017096026A1 (en) | 2015-12-02 | 2017-06-08 | Stcube, Inc. | Antibodies specific to glycosylated pd-1 and methods of use thereof |
| US20180362650A1 (en) * | 2015-12-07 | 2018-12-20 | Kyoto University | Pd-1 signal inhibitor combination therapy |
| CA2997406C (en) | 2015-12-09 | 2024-05-28 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies or cytokine release |
| MA44082A (fr) | 2015-12-14 | 2018-10-24 | Macrogenics Inc | Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation |
| CN105669864B (zh) | 2015-12-23 | 2018-10-16 | 杭州尚健生物技术有限公司 | 抗人程序性死亡受体1抗体及其制备方法和用途 |
| BR112018011029A2 (pt) | 2016-01-08 | 2018-11-21 | Hoffmann La Roche | métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits |
| CN109196121B (zh) * | 2016-02-29 | 2022-01-04 | 基因泰克公司 | 用于癌症的治疗和诊断方法 |
| TW202248213A (zh) | 2016-03-15 | 2022-12-16 | 日商中外製藥股份有限公司 | 使用pd-1軸結合拮抗劑和抗gpc3抗體治療癌症的方法 |
| MY198233A (en) | 2016-03-22 | 2023-08-15 | Hoffmann La Roche | Protease-Activated T Cell Bispecific Molecules |
| KR102418372B1 (ko) | 2016-03-29 | 2022-07-08 | 주식회사 에스티큐브 | 글리코실화된 pd-l1에 특이적인 이중 기능 항체 및 이의 사용 방법 |
| JP7572146B2 (ja) | 2016-03-29 | 2024-10-23 | エスティーキューブ アンド カンパニー，インコーポレイテッド | グリコシル化免疫チェックポイントタンパク質に特異的に結合する抗体を選択する方法 |
| CA3018989A1 (en) | 2016-04-04 | 2017-10-12 | Crititech, Inc. | Methods for solid tumor treatment |
| US20180157397A1 (en) * | 2016-04-08 | 2018-06-07 | Maxx Media Group, LLC | System and Method for Adding Three-Dimensional Images to an Intelligent Virtual Assistant that Appear to Project Forward of or Vertically Above an Electronic Display |
| MA45192A (fr) * | 2016-06-07 | 2019-04-10 | Macrogenics Inc | Traitement d'association |
| WO2018009916A1 (en) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
| CN109715666B (zh) | 2016-07-20 | 2023-02-21 | 斯特库比股份有限公司 | 癌症治疗方法和使用结合糖基化pd-l1的抗体的组合的疗法 |
| WO2018027204A1 (en) | 2016-08-05 | 2018-02-08 | Genentech, Inc. | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
| GB2568444A (en) | 2016-08-22 | 2019-05-15 | Twist Bioscience Corp | De novo synthesized nucleic acid libraries |
| US20190224200A1 (en) * | 2016-08-24 | 2019-07-25 | Ignyta, Inc. | Combinations for the treatment of cancer |
| US11382953B2 (en) * | 2016-08-26 | 2022-07-12 | Tetsuji Okuno | Microvascular blood flow decreasing agent and use thereof |
| MX2019002474A (es) * | 2016-09-01 | 2019-09-18 | Mayo Found Medical Education & Res | Composiciones de agente de unión de portador-ligando-1 de muerte programada y métodos de uso de las mismas para el tratamiento de cánceres. |
| WO2018048816A1 (en) | 2016-09-06 | 2018-03-15 | Mayo Foundation For Medical Education And Research | Methods of treating pd-l1 expressing cancer |
| JP6871364B2 (ja) | 2016-09-21 | 2021-05-12 | ツイスト バイオサイエンス コーポレーション | 核酸に基づくデータ保存 |
| EP3518970A1 (en) * | 2016-09-29 | 2019-08-07 | Genentech, Inc. | Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a taxane |
| SG11201901307VA (en) | 2016-09-29 | 2019-03-28 | Beijing Hanmi Pharmaceutical Co Ltd | Heterodimeric immunoglobulin constructs and preparation methods thereof |
| PL3519437T3 (pl) | 2016-09-30 | 2022-01-17 | F. Hoffmann-La Roche Ag | Przeciwciała dwuswoiste przeciwko p95HER2 |
| CA3039451A1 (en) | 2016-10-06 | 2018-04-12 | Pfizer Inc. | Dosing regimen of avelumab for the treatment of cancer |
| US20190290614A1 (en) * | 2016-11-09 | 2019-09-26 | Beth Israel Deaconess Medical Center, Inc. | Methods for Reducing Recurrence of Tumors |
| WO2018093821A1 (en) * | 2016-11-15 | 2018-05-24 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| CN109963876B (zh) * | 2016-11-18 | 2023-11-14 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| JP7169975B2 (ja) | 2016-12-16 | 2022-11-11 | ツイスト バイオサイエンス コーポレーション | 免疫シナプスの変異体ライブラリーおよびその合成 |
| CR20190376A (es) | 2017-01-17 | 2019-11-20 | Genentech Inc | Formulaciones de anticuerpos de her2 subcutáneas |
| TWI856437B (zh) * | 2017-01-20 | 2024-09-21 | 法商賽諾菲公司 | 抗TGF-β抗體及其用途 |
| TW202421659A (zh) | 2017-01-20 | 2024-06-01 | 美商健臻公司 | 骨靶向抗體 |
| US11046768B2 (en) | 2017-01-27 | 2021-06-29 | Memorial Sloan Kettering Cancer Center | Bispecific HER2 and CD3 binding molecules |
| EP3574012A1 (en) * | 2017-01-27 | 2019-12-04 | Memorial Sloan Kettering Cancer Center | Bispecific her2 and cd3 binding molecules |
| EP3586255B1 (en) | 2017-02-22 | 2025-01-15 | Twist Bioscience Corporation | Nucleic acid based data storage |
| WO2018156785A1 (en) * | 2017-02-22 | 2018-08-30 | Sutro Biopharma, Inc. | Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same |
| WO2018160794A1 (en) * | 2017-03-01 | 2018-09-07 | Merrimack Pharmaceuticals, Inc. | Epha2-targeted docetaxel -generating liposomes in combination with an agent that impedes regulatory t cell activity for treating cancer |
| KR20190096384A (ko) | 2017-03-02 | 2019-08-19 | 제넨테크, 인크. | Her2-양성 유방암 어쥬번트 치료 |
| CA3056388A1 (en) | 2017-03-15 | 2018-09-20 | Twist Bioscience Corporation | Variant libraries of the immunological synapse and synthesis thereof |
| WO2018178123A1 (en) * | 2017-03-29 | 2018-10-04 | Glycotope Gmbh | BISPECIFIC MUC-1 x PD-L1 ANTIBODIES |
| WO2018178047A1 (en) * | 2017-03-29 | 2018-10-04 | Glycotope Gmbh | Multispecific antibody constructs binding to muc1 and cd3 |
| CA3057758A1 (en) * | 2017-03-29 | 2018-10-04 | Glycotope Gmbh | Pd-l1 and ta-muc1 antibodies |
| JP7301002B2 (ja) | 2017-05-30 | 2023-06-30 | ブリストル－マイヤーズ スクイブ カンパニー | 抗ｌａｇ－３抗体または抗ｌａｇ－３抗体および抗ｐｄ－１もしくは抗ｐｄ－ｌ１抗体を含む組成物 |
| CA3060984A1 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Treatment of lag-3 positive tumors |
| US11168144B2 (en) | 2017-06-01 | 2021-11-09 | Cytomx Therapeutics, Inc. | Activatable anti-PDL1 antibodies, and methods of use thereof |
| SG11201909840TA (en) | 2017-06-09 | 2019-11-28 | Crititech Inc | Treatment of epithelial cysts by intracystic injection of antineoplastic particles |
| EP3638782A4 (en) | 2017-06-12 | 2021-03-17 | Twist Bioscience Corporation | SEALLESS NUCLEIC ACID ASSEMBLY METHODS |
| WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| KR20210118468A (ko) | 2017-06-14 | 2021-09-30 | 크리티테크, 인크. | 폐 장애의 치료 방법 |
| CN109134660B (zh) * | 2017-06-16 | 2022-07-01 | 上海恒润达生生物科技股份有限公司 | 靶向Mesothelin的嵌合抗原受体并联合表达抗PD1抗体的方法及其用途 |
| GB2581620A (en) | 2017-09-11 | 2020-08-26 | Twist Bioscience Corp | GPCR binding proteins and synthesis thereof |
| RU2020110399A (ru) | 2017-10-03 | 2021-11-09 | Крититек, Инк. | Местная доставка противоопухолевых частиц в комбинации с системной доставкой иммунотерапевтических агентов для лечения рака |
| WO2019079769A1 (en) | 2017-10-20 | 2019-04-25 | Twist Bioscience Corporation | HEATED NANOWELLS FOR THE SYNTHESIS OF POLYNUCLEOTIDES |
| CN120485344A (zh) | 2018-01-04 | 2025-08-15 | 特韦斯特生物科学公司 | 基于dna的数字信息存储 |
| EA202091630A1 (ru) | 2018-01-12 | 2020-12-04 | Инб Терапьютикс, Инк. | Дейтерированные соединения, композиции и способы для лечения раков, связанных с активацией etbr |
| SG11202007390YA (en) | 2018-02-08 | 2020-08-28 | Genentech Inc | Bispecific antigen-binding molecules and methods of use |
| WO2019153200A1 (zh) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| JP7418346B2 (ja) | 2018-04-13 | 2024-01-19 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | ４－１ＢＢＬを含むＨｅｒ２標的化抗原結合分子 |
| BR112020023373A2 (pt) | 2018-05-18 | 2021-02-09 | Daiichi Sankyo Company, Limited | conjugado, composição, e, uso de um conjugado ou de uma composição |
| JP2021526366A (ja) | 2018-05-18 | 2021-10-07 | ツイスト バイオサイエンス コーポレーション | 核酸ハイブリダイゼーションのためのポリヌクレオチド、試薬、および方法 |
| EP3624774A1 (en) * | 2018-05-31 | 2020-03-25 | Crititech, Inc. | Methods for isolating tumor-specific immune cells from a subject for adoptive cell therapy and cancer vaccines |
| TWI819011B (zh) * | 2018-06-23 | 2023-10-21 | 美商建南德克公司 | 以pd-1 軸結合拮抗劑、鉑劑及拓撲異構酶ii 抑制劑治療肺癌之方法 |
| CN111971387A (zh) | 2018-07-25 | 2020-11-20 | 阿特根公司 | 新型透明质酸水解酶突变体和包含其的药物组合物 |
| US20210246219A1 (en) * | 2018-08-27 | 2021-08-12 | Pieris Pharmaceuticals Gmbh | Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof |
| CN109053891B (zh) * | 2018-09-17 | 2021-12-21 | 苏州泓迅生物科技股份有限公司 | 一种抗pd-l1抗体及其制备方法和应用 |
| CA3124980A1 (en) | 2018-12-26 | 2020-07-02 | Twist Bioscience Corporation | Highly accurate de novo polynucleotide synthesis |
| AU2020227802A1 (en) | 2019-02-26 | 2021-10-14 | Twist Bioscience Corporation | Variant nucleic acid libraries for antibody optimization |
| US11492727B2 (en) | 2019-02-26 | 2022-11-08 | Twist Bioscience Corporation | Variant nucleic acid libraries for GLP1 receptor |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| AU2020298294A1 (en) | 2019-06-21 | 2022-02-17 | Twist Bioscience Corporation | Barcode-based nucleic acid sequence assembly |
| AR119382A1 (es) * | 2019-07-12 | 2021-12-15 | Hoffmann La Roche | Anticuerpos de pre-direccionamiento y métodos de uso |
| WO2021061842A1 (en) | 2019-09-23 | 2021-04-01 | Twist Bioscience Corporation | Variant nucleic acid libraries for single domain antibodies |
| AU2020356471A1 (en) | 2019-09-23 | 2022-04-21 | Twist Bioscience Corporation | Variant nucleic acid libraries for CRTH2 |
| CN110522909B (zh) * | 2019-09-30 | 2024-02-20 | 安徽省立医院 | 一种协同增强抗her2阳性肿瘤效果的药物组合 |
| CN114746448A (zh) * | 2019-12-04 | 2022-07-12 | 江苏康宁杰瑞生物制药有限公司 | 用于肿瘤治疗的双特异性融合蛋白 |
| MX2022009138A (es) * | 2020-01-23 | 2022-10-27 | Bioatla Inc | Anticuerpos y fragmentos de anticuerpos anti-her2 condicionalmente activos, sus inmunoconjugados y usos de estos. |
| US11780920B2 (en) | 2020-06-19 | 2023-10-10 | Hoffmann-La Roche Inc. | Antibodies binding to CD3 and CD19 |
| JP2023532122A (ja) | 2020-06-29 | 2023-07-26 | ジェネンテック， インコーポレイテッド | ペルツズマブにトラスツズマブを加えた固定用量配合剤 |
| US20230256092A1 (en) * | 2020-06-30 | 2023-08-17 | Shionogi & Co., Ltd. | Combined use of anti-ccr8 antibody and chemotherapeutic agent |
| CN116171167B (zh) * | 2020-07-20 | 2025-07-22 | 酵活英属哥伦比亚有限公司 | 包含配体-受体对和生物功能蛋白的融合蛋白 |
| EP3988568A1 (en) | 2020-10-21 | 2022-04-27 | Numab Therapeutics AG | Combination treatment |
| AU2021364837A1 (en) * | 2020-10-23 | 2023-05-25 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for lung cancer |
| CA3196076A1 (en) | 2020-11-04 | 2022-05-12 | Chi-Chung Li | Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies |
| US12516118B2 (en) | 2020-11-04 | 2026-01-06 | Genentech, Inc. | Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies and anti-CD79b antibody drug conjugates |
| MX2023005132A (es) | 2020-11-04 | 2023-05-25 | Genentech Inc | Dosificacion para el tratamiento con anticuerpos biespecificos anti-cd20/anti-cd3. |
| IL303350A (en) | 2020-12-04 | 2023-08-01 | Macrogenics Inc | Pharmaceutical compositions of a her2/neu antibody and use of the same |
| CN117083080A (zh) * | 2020-12-07 | 2023-11-17 | 健玛保 | 抗体和紫杉烷联合疗法 |
| CN114712512B (zh) * | 2021-01-06 | 2023-10-31 | 兰州大学第二医院 | 一种用于治疗her2阳性癌症的新型联合疗法 |
| KR20240005691A (ko) | 2021-04-30 | 2024-01-12 | 에프. 호프만-라 로슈 아게 | 항-cd20/항-cd3 이중특이적 항체 및 항-cd79b 항체 약물 접합체를 이용한 병용 치료를 위한 투약 |
| AU2022273541A1 (en) | 2021-05-14 | 2023-11-30 | Genentech, Inc. | Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin |
| CN115400115B (zh) * | 2021-05-26 | 2025-01-14 | 石药集团中奇制药技术（石家庄）有限公司 | 多西他赛白蛋白组合物和免疫检查点抑制剂的组合及用途 |
| CN114395047B (zh) * | 2021-12-07 | 2023-11-07 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
| WO2023144973A1 (ja) | 2022-01-27 | 2023-08-03 | 中外製薬株式会社 | 抗ｖｅｇｆ抗体及びパクリタキセルと組み合わせて使用する抗ｐｄ－ｌ１抗体を含む医薬組成物 |
| CA3247048A1 (en) | 2022-04-13 | 2023-10-19 | Genentech, Inc. | PHARMACEUTICAL COMPOSITIONS OF MOSUNETUZUMAB AND METHODS OF USE |
| WO2024140919A1 (zh) * | 2022-12-29 | 2024-07-04 | 南京圣和药业股份有限公司 | 抗crtam/抗pd-l1抗体及其应用 |
| WO2025090881A1 (en) * | 2023-10-27 | 2025-05-01 | Huyabio International, Llc | Combination therapies of wdr5 inhibitors and pd-1 inhibitors |
| WO2025167357A1 (zh) * | 2024-02-06 | 2025-08-14 | 启愈生物技术(上海)有限公司 | Cd80/taa融合蛋白相关的肿瘤靶向、t细胞激活分子形式及其应用 |
Family Cites Families (193)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH542802A (de) | 1967-10-31 | 1973-10-15 | Givaudan & Cie Sa | Verfahren zur Herstellung eines Myrcenderivates |
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| DE68925971T2 (de) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE68913658T3 (de) | 1988-11-11 | 2005-07-21 | Stratagene, La Jolla | Klonierung von Immunglobulin Sequenzen aus den variablen Domänen |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP0479909B1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| EP0491007B1 (en) | 1989-09-08 | 1996-03-13 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DK0710719T3 (da) | 1990-01-12 | 2007-07-09 | Amgen Fremont Inc | Frembringelse af xenogene antistoffer |
| WO1992000373A1 (en) | 1990-06-29 | 1992-01-09 | Biosource Genetics Corporation | Melanin production by transformed microorganisms |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| CA2102511A1 (en) | 1991-05-14 | 1992-11-15 | Paul J. Higgins | Heteroconjugate antibodies for treatment of hiv infection |
| WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| JP3951062B2 (ja) | 1991-09-19 | 2007-08-01 | ジェネンテック・インコーポレーテッド | 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用 |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| ATE503496T1 (de) | 1992-02-06 | 2011-04-15 | Novartis Vaccines & Diagnostic | Biosynthetisches bindeprotein für tumormarker |
| JPH08500017A (ja) | 1992-08-17 | 1996-01-09 | ジェネンテク，インコーポレイテッド | 二特異的免疫アドヘジン |
| NZ258392A (en) | 1992-11-13 | 1997-09-22 | Idec Pharma Corp | Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| DE69428764T2 (de) | 1993-12-24 | 2002-06-20 | Merck Patent Gmbh | Immunokonjugate |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| HU216142B (hu) | 1994-07-21 | 1999-04-28 | Akzo Nobel N.V. | Ciklusos keton-peroxidokat tartalmazó kompozíciók, és azok alkalmazása (ko)polimerek módosítására |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| ES2332984T3 (es) | 1995-03-30 | 2010-02-16 | Pfizer Products Inc. | Derivados de quinazolinas. |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| EP0831880A4 (en) | 1995-06-07 | 2004-12-01 | Imclone Systems Inc | ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH |
| WO1997002266A1 (en) | 1995-07-06 | 1997-01-23 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| CN1923818A (zh) | 1996-04-12 | 2007-03-07 | 沃尼尔·朗伯公司 | 酪氨酸激酶的不可逆抑制剂 |
| ATE227283T1 (de) | 1996-07-13 | 2002-11-15 | Glaxo Group Ltd | Kondensierte heterozyklische verbindungen als protein kinase inhibitoren |
| ES2332893T3 (es) | 1996-08-30 | 2010-02-15 | Upfront Chromatography A/S | Aislamiento de inmunoglobulinas. |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| ATE549918T1 (de) | 1996-12-03 | 2012-04-15 | Amgen Fremont Inc | Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden |
| US20080318254A9 (en) | 1997-03-10 | 2008-12-25 | The Regents Of The University Of California | PSCA antibodies and hybridomas producing them |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US20020173629A1 (en) | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
| AU7165698A (en) | 1997-05-06 | 1998-11-27 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| PT994903E (pt) | 1997-06-24 | 2005-10-31 | Genentech Inc | Metodos e composicoes para glicoproteinas galactosiladas |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| BR9814116A (pt) | 1997-11-06 | 2000-10-03 | American Cyanamid Co | Uso de derivados de quinazolina como inibidores de cinase de tirosina para tratamento de pólipo colÈnico |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| BR9813365A (pt) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Método para produção e humanização de um anticorpo monoclonal de rato |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
| US20030175884A1 (en) | 2001-08-03 | 2003-09-18 | Pablo Umana | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| DE69942021D1 (de) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
| BR9915487A (pt) | 1998-11-19 | 2001-07-31 | Warner Lambert Co | N-[4-(3-cloro-4-flúor-fenilamino) - 7 - (3-morfolin-4-il-propóxi)-quinazolin-6-il]-acrilamida, um inibidor irreversìvel de tirosina quinases |
| CN1763097B (zh) | 1999-01-15 | 2011-04-13 | 杰南技术公司 | 具有改变的效应功能的多肽变体 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| WO2000058499A1 (fr) | 1999-03-30 | 2000-10-05 | Japan Tobacco Inc. | Procede pour la production d'anticorps monoclonal |
| PT1914244E (pt) | 1999-04-09 | 2013-07-26 | Kyowa Hakko Kirin Co Ltd | Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| AU782626B2 (en) | 1999-10-04 | 2005-08-18 | Medicago Inc. | Method for regulating transcription of foreign genes |
| EP1229125A4 (en) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING A POLYPEPTIDE |
| EP1240319A1 (en) | 1999-12-15 | 2002-09-18 | Genentech, Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| WO2002031140A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| JP2005519580A (ja) | 2001-05-16 | 2005-07-07 | アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ | 非ヒト動物由来のヒト抗肺炎球菌抗体 |
| AU2002332628B2 (en) | 2001-08-23 | 2007-07-26 | Genmab A/S | Human antibodies specific for interleukin 15 (IL-15) |
| BR0213761A (pt) | 2001-10-25 | 2005-04-12 | Genentech Inc | Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US20040132140A1 (en) | 2002-04-09 | 2004-07-08 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
| AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
| US20050031613A1 (en) | 2002-04-09 | 2005-02-10 | Kazuyasu Nakamura | Therapeutic agent for patients having human FcgammaRIIIa |
| WO2003085102A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cell with depression or deletion of the activity of protein participating in gdp-fucose transport |
| WO2003085107A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cells with modified genome |
| JPWO2003084569A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物含有医薬 |
| JP4753578B2 (ja) | 2002-06-03 | 2011-08-24 | ジェネンテック， インコーポレイテッド | 合成抗体ファージライブラリー |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| BRPI0316779B1 (pt) | 2002-12-16 | 2020-04-28 | Genentech Inc | anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados |
| WO2004065416A2 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| CN1761482A (zh) | 2003-01-17 | 2006-04-19 | 纽约州立大学研究基金会 | 与胰腺癌相关的抗原、针对它的抗体以及诊断和治疗方法 |
| WO2004064734A2 (en) * | 2003-01-17 | 2004-08-05 | Threshold Pharmaceuticals, Inc. | Combination therapies for the treatment of cancer |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| AU2004270103B2 (en) | 2003-05-21 | 2012-02-23 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies against Bacillusanthracis protective antigen |
| RU2005141512A (ru) | 2003-05-31 | 2007-07-20 | Микромет Аг (De) | Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками |
| JPWO2005035586A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | 融合蛋白質組成物 |
| US20070134759A1 (en) | 2003-10-09 | 2007-06-14 | Harue Nishiya | Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase |
| DE602004026470D1 (de) | 2003-11-05 | 2010-05-20 | Roche Glycart Ag | Fc-rezeptor und effektorfunktion |
| EP2186527A1 (en) | 2003-11-28 | 2010-05-19 | Micromet AG | Compositions comprising polypeptides |
| WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| ZA200608130B (en) | 2004-03-31 | 2008-12-31 | Genentech Inc | Humanized anti-TGF-beta antibodies |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| EP2374817B1 (en) | 2004-04-13 | 2017-09-06 | F. Hoffmann-La Roche AG | Anti-P-selectin antibodies |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| AU2006244885B2 (en) | 2005-05-09 | 2011-03-31 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| AU2006265108C1 (en) * | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
| EP3178850B1 (en) | 2005-10-11 | 2021-01-13 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| US8679490B2 (en) | 2005-11-07 | 2014-03-25 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
| US20070237764A1 (en) | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| CA2651567A1 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| CA2663521A1 (en) * | 2006-09-20 | 2008-07-17 | The Johns Hopkins University | Combinatorial therapy of cancer and infectious diseases with anti-b7-h1 antibodies |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| EP3461842A1 (en) | 2007-04-03 | 2019-04-03 | Amgen Research (Munich) GmbH | Cross-species-specific binding domain |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| WO2009089149A1 (en) | 2008-01-03 | 2009-07-16 | The Johns Hopkins University | B7-h1 (cd274) antagonists induce apoptosis of tumor cells |
| EP2242773B1 (en) * | 2008-02-11 | 2017-06-14 | Cure Tech Ltd. | Monoclonal antibodies for tumor treatment |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| AR072999A1 (es) * | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| MX2011002250A (es) | 2008-08-25 | 2011-08-17 | Amplimmune Inc | Antagonistas de muerte celular programada-1 y métodos de uso de los mismos. |
| PT2376535T (pt) * | 2008-12-09 | 2017-06-23 | Hoffmann La Roche | Anticorpos anti-pd-l1 e a sua utilização para a melhoria do funcionamento das células t |
| WO2011066389A1 (en) | 2009-11-24 | 2011-06-03 | Medimmmune, Limited | Targeted binding agents against b7-h1 |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| AU2011205343B2 (en) * | 2010-01-12 | 2015-08-13 | Nestec S.A. | Methods for predicting response of triple-negative breast cancer to therapy |
| WO2011093512A1 (en) * | 2010-01-27 | 2011-08-04 | Takeda Pharmaceutical Company Limited | Compounds for suppressing a peripheral nerve disorder induced by an anti - cancer agent |
| EP2571577A1 (en) * | 2010-05-17 | 2013-03-27 | Bristol-Myers Squibb Company | Improved immunotherapeutic dosing regimens and combinations thereof |
| WO2012143524A2 (en) * | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
| JP6238459B2 (ja) * | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| PL4234033T3 (pl) | 2011-10-14 | 2025-04-28 | F. Hoffmann-La Roche Ag | Zastosowania i wyrób przemysłowy zawierający pertuzumab, inhibitor dimeryzacji HER2 |
| CA2856895C (en) * | 2011-11-28 | 2021-10-26 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
| EP2660324A1 (en) * | 2012-05-02 | 2013-11-06 | Algenics | Production of secreted therapeutic antibodies in microalgae |
| IN2014DN09582A (enExample) * | 2012-05-15 | 2015-07-17 | Diatech Oncology Llc | |
| CA3213528A1 (en) * | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| EP2854843A4 (en) * | 2012-05-31 | 2016-06-01 | Sorrento Therapeutics Inc | ANTIGEN-BINDING PROTEINS FOR BINDING PD-L1 |
| US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| US9149455B2 (en) * | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| MX363188B (es) * | 2012-11-30 | 2019-03-13 | Hoffmann La Roche | Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1. |
| EP2944323B1 (en) | 2013-01-11 | 2019-03-27 | Dingfu Biotarget Co., Ltd | Agents for treating tumours, use and method thereof |
| US20150071910A1 (en) * | 2013-03-15 | 2015-03-12 | Genentech, Inc. | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
| KR20230070054A (ko) | 2013-03-15 | 2023-05-19 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
| SG11201509742QA (en) * | 2013-06-03 | 2015-12-30 | Novartis Ag | Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor |
| AR097306A1 (es) * | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| IL312865B2 (en) * | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| AR097584A1 (es) * | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| US10202454B2 (en) | 2013-10-25 | 2019-02-12 | Dana-Farber Cancer Institute, Inc. | Anti-PD-L1 monoclonal antibodies and fragments thereof |
| MX2016005283A (es) * | 2013-10-25 | 2017-02-20 | Pharmacyclics Llc | Tratamiento que utiliza inhibidores de tirosina quinasa de bruton e inmunoterapia. |
| LT3083686T (lt) * | 2013-12-17 | 2020-01-10 | F. Hoffmann-La Roche Ag | Vėžinių ligų gydymo būdai naudojant pd-1 ašies rišimosi antagonistus ir taksanus |
| BR112016026559A8 (pt) † | 2014-05-15 | 2021-07-13 | Bristol Myers Squibb Co | uso de um anticorpo anti-pd-1 e outro agente anticâncer em combinação com quimioterapia dupla com base em platina (pt-dc) e kit |
| KR102689256B1 (ko) | 2015-06-17 | 2024-07-30 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법 |
-
2014
- 2014-12-17 LT LTEP14824700.0T patent/LT3083686T/lt unknown
- 2014-12-17 CA CA2931812A patent/CA2931812A1/en active Pending
- 2014-12-17 MX MX2016007887A patent/MX2016007887A/es unknown
- 2014-12-17 ES ES14824700T patent/ES2763429T5/es active Active
- 2014-12-17 EP EP14824700.0A patent/EP3083686B2/en active Active
- 2014-12-17 WO PCT/US2014/070974 patent/WO2015095404A2/en not_active Ceased
- 2014-12-17 CN CN201480068837.8A patent/CN105828837B/zh active Active
- 2014-12-17 RU RU2016126662A patent/RU2719487C2/ru active
- 2014-12-17 PT PT148247000T patent/PT3083686T/pt unknown
- 2014-12-17 SI SI201431426T patent/SI3083686T2/sl unknown
- 2014-12-17 JP JP2016539949A patent/JP2017507900A/ja not_active Withdrawn
- 2014-12-17 IL IL296657A patent/IL296657A/en unknown
- 2014-12-17 HK HK16114034.1A patent/HK1225634A1/zh unknown
- 2014-12-17 AU AU2014364587A patent/AU2014364587C1/en active Active
- 2014-12-17 SG SG10201808519VA patent/SG10201808519VA/en unknown
- 2014-12-17 SG SG11201604956SA patent/SG11201604956SA/en unknown
- 2014-12-17 MX MX2016007972A patent/MX389667B/es unknown
- 2014-12-17 NZ NZ760065A patent/NZ760065A/en unknown
- 2014-12-17 KR KR1020247002877A patent/KR20240017102A/ko not_active Ceased
- 2014-12-17 SG SG11201604995YA patent/SG11201604995YA/en unknown
- 2014-12-17 CN CN201480073552.3A patent/CN105934253A/zh active Pending
- 2014-12-17 KR KR1020167017848A patent/KR102447878B1/ko active Active
- 2014-12-17 PL PL14824700.0T patent/PL3083686T5/pl unknown
- 2014-12-17 HU HUE14824700A patent/HUE047699T2/hu unknown
- 2014-12-17 KR KR1020227032906A patent/KR102630750B1/ko active Active
- 2014-12-17 KR KR1020257002810A patent/KR20250024856A/ko active Pending
- 2014-12-17 MY MYPI2016001060A patent/MY189089A/en unknown
- 2014-12-17 CN CN202011041090.0A patent/CN112353943A/zh active Pending
- 2014-12-17 HR HRP20192288TT patent/HRP20192288T4/hr unknown
- 2014-12-17 BR BR112016013896A patent/BR112016013896A2/pt not_active Application Discontinuation
- 2014-12-17 EP EP20151180.5A patent/EP3680254A1/en not_active Withdrawn
- 2014-12-17 DK DK14824700.0T patent/DK3083686T4/da active
- 2014-12-17 EP EP14833308.1A patent/EP3083692B1/en active Active
- 2014-12-17 EP EP19191009.0A patent/EP3647324A1/en active Pending
- 2014-12-17 NZ NZ720515A patent/NZ720515A/en unknown
- 2014-12-17 AU AU2014364601A patent/AU2014364601A1/en not_active Abandoned
- 2014-12-17 JP JP2016539319A patent/JP6841656B2/ja active Active
- 2014-12-17 WO PCT/US2014/070992 patent/WO2015095418A1/en not_active Ceased
- 2014-12-17 RS RS20191594A patent/RS59659B2/sr unknown
- 2014-12-17 FI FIEP14824700.0T patent/FI3083686T4/fi active
- 2014-12-17 SG SG10202002334PA patent/SG10202002334PA/en unknown
- 2014-12-17 CA CA2933883A patent/CA2933883A1/en not_active Abandoned
- 2014-12-17 KR KR1020167018821A patent/KR20160089531A/ko not_active Ceased
-
2016
- 2016-05-25 IL IL245857A patent/IL245857B2/en unknown
- 2016-05-27 US US15/167,125 patent/US10570213B2/en active Active
- 2016-06-02 ZA ZA2016/03753A patent/ZA201603753B/en unknown
- 2016-06-15 IL IL246228A patent/IL246228A0/en unknown
- 2016-06-16 US US15/184,966 patent/US20170008971A1/en not_active Abandoned
- 2016-06-16 MX MX2021013520A patent/MX2021013520A/es unknown
-
2019
- 2019-04-09 JP JP2019074325A patent/JP2019142900A/ja active Pending
-
2020
- 2020-01-13 US US16/741,526 patent/US20200131276A1/en not_active Abandoned
- 2020-03-02 JP JP2020034955A patent/JP2020111580A/ja not_active Withdrawn
- 2020-08-19 US US16/997,646 patent/US20200392249A1/en not_active Abandoned
- 2020-09-15 AU AU2020233642A patent/AU2020233642B2/en active Active
-
2021
- 2021-03-09 US US17/196,457 patent/US20210189004A1/en not_active Abandoned
- 2021-09-23 US US17/483,281 patent/US20220002437A1/en not_active Abandoned
-
2022
- 2022-01-04 JP JP2022000201A patent/JP7645204B2/ja active Active
- 2022-04-01 US US17/711,170 patent/US20220306766A1/en not_active Abandoned
- 2022-12-16 US US18/067,407 patent/US20230203194A1/en not_active Abandoned
-
2023
- 2023-09-29 US US18/477,924 patent/US20240076404A1/en not_active Abandoned
-
2024
- 2024-05-08 US US18/657,996 patent/US20240309111A1/en not_active Abandoned
- 2024-10-11 JP JP2024179266A patent/JP2025020147A/ja active Pending
- 2024-11-22 US US18/956,269 patent/US20250084185A1/en not_active Abandoned
-
2025
- 2025-01-17 US US19/027,348 patent/US20250154282A1/en active Pending
- 2025-10-07 US US19/351,816 patent/US20260028419A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017507900A5 (enExample) | ||
| JP2017501167A5 (enExample) | ||
| JP2009541492A5 (enExample) | ||
| JP2019502712A5 (enExample) | ||
| JP2022058802A5 (enExample) | ||
| HRP20240626T1 (hr) | Bispecifična antitijela protiv ceacam5 i cd3 | |
| JP2012501626A5 (enExample) | ||
| JP2014158469A5 (enExample) | ||
| HRP20201595T1 (hr) | Anti-pd-l1 protutijela i njihova uporaba | |
| JP2017514461A5 (enExample) | ||
| RU2019134352A (ru) | Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap | |
| JP2015500207A5 (enExample) | ||
| JP2017534577A5 (enExample) | ||
| JP2018503365A5 (enExample) | ||
| JP2018534933A5 (enExample) | ||
| CN109311978B (zh) | Dsg2单克隆抗体和其用途 | |
| RU2017121096A (ru) | Комбинированная терапия, включающая применение ох40-связывающих агонистов и антагонистов связывания оси pd-1 | |
| RU2017118225A (ru) | Антитела к PD-1 и способы их применения | |
| JP2018505177A5 (enExample) | ||
| FI3736292T3 (fi) | CD3-vasta-aineita ja käyttömenetelmiä | |
| JP2017529838A5 (enExample) | ||
| CN110799543A (zh) | 肝细胞癌的免疫治疗 | |
| CN104684552A (zh) | 组合及其用途 | |
| CN107108727A (zh) | 对人vegf‑a有异常强的结合亲和力并具有与人vegf‑b的交叉反应性的抗人vegf抗体 | |
| RU2018107693A (ru) | Комбинированные виды лечения и их варианты применения и способы |